Shouryadeep Srivastava

Deep Srivastava, M.D., Ph.D., is Vice President of Clinical Development at Theseus Pharmaceuticals. Dr. Srivastava has 13 years of clinical research experience in the biotechnology and pharmaceuticals industry. He most recently served as Vice President, Clinical Development at iTeos Therapeutics where he led the clinical development activity for immunotherapies being developed for solid tumors. In his role at iTeos, he led successful IND clearance by the FDA for a Phase 2 lung cancer trial and was responsible for the clinical strategy, monitoring, and oversight activities. Prior to that from 2018 through 2021, Deep held positions of increasing responsibility at Takeda and played a pivotal role in sNDA approval, Phase 3 initiation, and pediatric development for a leukemia drug, ICLUSIG® (ponatinib), as the Global Clinical Lead. Earlier in his career, he was a member of the Baxalta/Shire Hematology clinical team and also held medical writing and other roles in different companies. Dr. Srivastava received his M.D. from B.R.D. Medical College, India, and his Ph.D. from Texas Tech University.